MedTrace Logo

Treatment of Lung Adenocarcinoma With Bronchioloalveolar Feature

NCT00198380 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2024-03-08

No results posted yet for this study

Summary

Pneumonic adenocarcinoma (P-ADC) is defined as a primary lung ADC with a radiological pneumonic presentation, usually referred to histologically as ADC with a mixed-invasive and BAC predominant subtype in the 2004 WHO classification. Surgery is the best therapy for resectable tumors since the effectiveness of chemotherapy is disappointing. In the advanced P-ADC diffuse/multifocal types of BAC, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) (gefitinib and erlotinib) have shown promise, with some rapid, dramatic responses, possibly reflecting specific molecular differences from other non-small cell lung carcinomas.

Conditions

  • Pneumonic-type Adenocarcinoma (P-ADC)
  • Lung Adenocarcinoma With Bronchiolo-alveolar Feature

Interventions

DRUG

Gefitinib

Gefitinib 250 mg/day, until progression or severe toxicity

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Intergroupe Francophone de Cancerologie Thoracique

    lead OTHER

Principal Investigators

  • Jacques Cadranel, Pr · Intergroupe Francophone de Cancerologie Thoracique

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-04-30
Primary Completion
2008-12-31
Completion
2009-12-31

Countries

  • France

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00198380 on ClinicalTrials.gov